Kintara Therapeutics (Kintara Therapeutics) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Kintara Therapeutics is: No Data: Cannot be evaluated.

Competitive Comparison of Kintara Therapeutics's Risk Assessment

For the Biotechnology subindustry, Kintara Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Risk Assessment falls into.

Kintara Therapeutics (NAS:KTRA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Kintara Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics (Kintara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

3DMA:Germany 3DMA:Germany

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Executives

Robert Hoffman	director, officer: President and CEO	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill	officer: Chief Financial Officer	2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian	director, officer: Head of Strategic Partnerships	P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr	director	543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown	officer: Chief Scientific Officer	100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos	director, officer: SVP, Business Development	12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell	director	38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara	director	550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston	director	4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr	director	8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha	director	SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010